Literature DB >> 11669602

Identification of EBV transforming genes by recombinant EBV technology.

K M Izumi1.   

Abstract

Epstein-Barr virus (EBV) is able to infect primary B-lymphocytes but usually does not proceed to replicate more virions. Instead, EBV persists as an incomplete virus and expresses 12 gene products that transform the growth of these cells into continuously proliferating lymphoblastoid cell lines. Because EBV is associated with several human malignancies, there is intense interest in delineating the molecular functions of these EBV gene products in transformation. This review focuses on the recombinant EBV technologies that have been developed to introduce specific mutations into EBV and test the functions of these EBV genes in primary B-lymphocyte growth transformation. Copyright 2001 Academic Press.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11669602     DOI： 10.1006/scbi.2001.0407

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  10 in total

1.  Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus.

Authors:  Charles M Chau; Paul M Lieberman
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.

Authors:  Pamela M Pegman; Sinéad M Smith; Brendan N D'Souza; Sinéad T Loughran; Sabine Maier; Bettina Kempkes; Paul A Cahill; Matthew J Simmons; Céline Gélinas; Dermot Walls
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Characterization of the rapamycin-inducible EBV LMP1 activation system.

Authors:  Sang Yong Kim; Jung-Eun Kim; Jiyeon Won; Yoon-Jae Song
Journal:  J Microbiol       Date:  2015-10-02       Impact factor: 3.422

4.  Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system.

Authors:  Teru Kanda; Misako Yajima; Nazmul Ahsan; Mika Tanaka; Kenzo Takada
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor.

Authors:  Brendan N D'Souza; Leonard C Edelstein; Pamela M Pegman; Sinéad M Smith; Sinéad T Loughran; Ann Clarke; Anja Mehl; Martin Rowe; Céline Gélinas; Dermot Walls
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Epstein-Barr virus regulates STAT1 through latent membrane protein 1.

Authors:  Ciarán Richardson; Ceri Fielding; Martin Rowe; Paul Brennan
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Epstein-Barr virus genetics: talking about the BAC generation.

Authors:  Regina Feederle; Emmalene J Bartlett; Henri-Jacques Delecluse
Journal:  Herpesviridae       Date:  2010-12-07

8.  The Epstein-Barr virus latent membrane protein-1 (LMP1) 30-bp deletion and XhoI-polymorphism in nasopharyngeal carcinoma: a meta-analysis of observational studies.

Authors:  Vivaldo G da Costa; Ariany C Marques-Silva; Marcos L Moreli
Journal:  Syst Rev       Date:  2015-04-13

9.  Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type.

Authors:  Jing-Hua Wang; Xi-Wen Bi; Peng-Fei Li; Zhong-Jun Xia; Hui-Qiang Huang; Wen-Qi Jiang; Yu-Jing Zhang; Liang Wang
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

10.  Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via the EGFR/Ca2+/calpain/ITGβ4 axis.

Authors:  Jiezhen Liang; Shixing Zheng; Xue Xiao; Jiazhang Wei; Zhe Zhang; Ingemar Ernberg; Liudmila Matskova; Guangwu Huang; Xiaoying Zhou
Journal:  Biol Open       Date:  2017-06-15       Impact factor: 2.422
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.